KPI data tables
Novavax operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Cash + marketable securities + restricted cash |
|---|---|
| Q3 2026 | 627 |
| Q2 2026 | 723.9 |
| Q1 2026 | 794.9 |
| Q4 2025 | 750.5 |
| Q3 2025 | 778.2 |
| Q2 2025 | 627.5 |
| Q1 2025 | 746.6 |
| Q4 2024 | 938.2 |
Source: Novavax selected consolidated balance sheet data in quarterly earnings releases and 10-K/10-Q liquidity notes. Cash equals cash and cash equivalents plus marketable securities plus restricted cash (thousands divided by 1,000). Q4 2024 and Q4 2025: FY 2025 Form 10-K (https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/nvax-20251231.htm) $938.2 million and $750.5 million. Q1 2025 Exhibit 99.1 (https://ir.novavax.com/press-releases/2025-05-08-Novavax-Reports-First-Quarter-2025-Financial-Results-and-Operational-Highlights): $263,338 / $468,141 / $15,142. Q2 2025 Exhibit 99.1 (https://ir.novavax.com/press-releases/2025-08-06-Novavax-Reports-Second-Quarter-2025-Financial-Results-and-Operational-Highlights): $253,744 / $358,560 / $15,238. Q3 2025 Exhibit 99.1 (https://ir.novavax.com/press-releases/2025-11-06-Novavax-Reports-Third-Quarter-2025-Financial-Results-and-Operational-Highlights): $268,023 / $494,871 / $15,334. Q1 2026 Exhibit 99.1 (https://www.sec.gov/Archives/edgar/data/1000694/000162828026030924/nvaxq1-26earningspressrele.htm): $228,363 / $561,969 / $4,562. Q2 2026 Exhibit 99.1 (https://www.sec.gov/Archives/edgar/data/1000694/000100069426000019/prfinal.htm) and Form 10-Q (accession 0001000694-26-000018): $191,458 / $527,882 / $4,582. Q3 2026 Exhibit 99.1 filed 2026-11-05 (https://www.sec.gov/Archives/edgar/data/1000694/000100069426000021/nvax3q26earningspressrelea.htm) and Form 10-Q (accession 0001000694-26-000022, https://www.sec.gov/Archives/edgar/data/1000694/000100069426000022/nvax-20260930.htm): $222,455 / $399,908 / $4,602. MidCap $330 million facility and $50 million initial draw: FY 2025 results release (26 Feb 2026) and Q1 2026 10-Q. $100 million unrestricted-cash covenant: FY 2025 10-K Credit Agreement discussion.
| Period | Deferred revenue |
|---|---|
| Q3 2026 | 432.2 |
| Q2 2026 | 443.3 |
| Q1 2026 | 448 |
| Q4 2025 | 499 |
| Q3 2025 | 501.4 |
| Q2 2025 | 513 |
| Q1 2025 | 517.9 |
| Q4 2024 | 1,121.9 |
| Q3 2024 | 1,128.8 |
| Q2 2024 | 1,199.8 |
| Q1 2024 | 1,082.4 |
| Q4 2023 | 863.5 |
| Q3 2023 | 801 |
| Q2 2023 | 907.4 |
| Q1 2023 | 689.8 |
| Q4 2022 | 549.6 |
| Q3 2022 | 1,440.2 |
| Q2 2022 | 1,516.1 |
| Q1 2022 | 1,536 |
| Q4 2021 | 1,595.5 |
| Q4 2020 | 273.2 |
Source: Novavax Form 10-Q and Form 10-K deferred-revenue / contract-liability balances, SEC XBRL us-gaap:ContractWithCustomerLiability (https://data.sec.gov/api/xbrl/companyconcept/CIK0001000694/us-gaap/ContractWithCustomerLiability.json). USD millions, later filing wins on restatement. Window Q4 2020–Q3 2026. Q1 2021–Q3 2021 omitted (no period-end tag). Canada APA $555.7 million current deferred revenue at December 31, 2024 and $575.7 million recognized as product sales in Q1 2025: FY 2025 10-K (https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/nvax-20251231.htm). Q3 2026 deferred revenue $432.2 million (current $102.201 million plus non-current $330.011 million): Form 10-Q for September 30, 2026, filed 2026-11-05 (https://www.sec.gov/Archives/edgar/data/1000694/000100069426000022/nvax-20260930.htm). Remaining unsatisfied transaction price $0.5 billion of which $0.4 billion in deferred revenue at September 30, 2026: Q3 2026 10-Q (rounded, not plotted).